Mode
Text Size
Log in / Sign up
N/A Completed N=255

This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry

Arthritis, Rheumatoid
Source: ClinicalTrials.gov NCT05375942 ↗
Enrolled (actual)
255
Serious AEs
Results posted
Apr 2024
Primary outcomePrimary: Percentage of Participants Who Achieved Low Disease Activity (LDA) at 6 Months After Inflectra Initiation — 32.9 Percentage of participants

Summary

This is a retrospective observational study looking at the characteristics and outcomes of participants taking Inflectra using the CorEvitas Rheumatoid Arthritis Registry.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants Who Achieved Low Disease Activity (LDA) at 6 Months After Inflectra Initiation
32.9
SECONDARY
Percentage of Participants Who Achieved Clinical Remission at 6 Months After Inflectra Initiation
13.7
SECONDARY
Change From Baseline in CDAI at 6 Months After Inflectra Initiation
-1.8
SECONDARY
Change From Baseline in Health Assessment Questionnaire (HAQ) at 6 Months After Inflectra Initiation
-0.0
SECONDARY
Change From Baseline in Participant Pain Assessment at 6 Months After Inflectra Initiation
-0.5
SECONDARY
Change From Baseline in Participant Fatigue Assessment at 6 Months After Inflectra Initiation
-1.4
SECONDARY
Percentage of Participants With a Modified American College of Rheumatology 20 Percent (%) (mACR20) Response at 6 Months After Inflectra Initiation
12.6
SECONDARY
Percentage of Participants With mACR50 at 6 Months After Inflectra Initiation
8.4
SECONDARY
Percentage of Participants With mACR70 at 6 Months After Inflectra Initiation
4.2

Eligibility Criteria

Inclusion Criteria

  • Be at least 18 years of age
  • Have been diagnosed with RA by a rheumatologist
  • Have initiated treatment with Inflectra
  • Had assessment of effectiveness in patients who have at least one follow up visit.

Exclusion Criteria

  • No additional exclusion criteria
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05375942). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search